تحميل...
Phase I Study Evaluating the Combination of Lapatinib (a Her2/Neu and EGFR Inhibitor) and Everolimus (an mTOR Inhibitor) in Patients with Advanced Cancers: South West Oncology Group (SWOG) Study S0528
PURPOSE: Everolimus, an oral inhibitor of mTOR, can augment the efficacy of HER inhibitors in pre-clinical studies. This study was conducted to determine the safety and pharmacokinetics (PK) of the combination of lapatinib, a Her1 and 2 inhibitor, and everolimus, and to describe its antitumor activi...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
2013
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4072025/ https://ncbi.nlm.nih.gov/pubmed/24057042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2297-4 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|